EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study

Molecular Imaging

Volumn 14, Issue 6, 2015, Pages 385-395

  Puttick, Simon ^b   Stringer, Brett W ^b   Day, Bryan W ^b   Bruce, Zara C ^b   Ensbey, Kathleen S ^b   Mardon, Karine ^b   Cowin, Gary J ^b   Thurecht, Kristofer J ^b   Whittaker, Andrew K ^b   Fay, Michael ^b   Boyd, Andrew W ^b   Rose, Stephen ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; COMPUTER AIDED DIAGNOSIS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MONOCLONAL ANTIBODIES; PATIENT TREATMENT; POSITRONS; TUMORS;

CRITICAL TECHNOLOGIES; DIAGNOSTIC IMAGING; IMAGE GUIDED THERAPY; NON-INVASIVE IMAGING; POSITRON EMISSION TOMOGRAPHY (PET); RECEPTOR TYROSINE KINASE; TREATMENT PLANNING; TUMOR PROGRESSIONS;

POSITRON EMISSION TOMOGRAPHY;

1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; CONTRAST MEDIUM; EPHRIN RECEPTOR A2; HETEROCYCLIC COMPOUND; MONOCLONAL ANTIBODY;

ANIMAL; BRAIN; BRAIN TUMOR; DRUG SCREENING; GLIOBLASTOMA; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, EPHA2; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942863596     PISSN: 15353508     EISSN: 15360121     Source Type: Journal    
DOI: 10.2310/7290.2015.00008     Document Type: Article

References (49)

1. Symms M, Jager HR, Schmierer K, Yousry TA. A review of structural magnetic resonance neuroimaging. J Neurol Neurosurg Psychiatry 2004;75:1235-44, doi:10.1136/jnnp.2003.032714.
2. Le Bihan D, Johansen-Berg H. Diffusion MRI at 25: exploring brain tissue structure and function. Neuroimage 2012;61: 324-41, doi:10.1016/j.neuroimage.2011.11.006.
3. Decharms RC. Applications of real-time fMRI. Nat Rev Neurosci 2008;9:720-9, doi:10.1038/nrn2414.
4. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-22, doi:10.1002/jmri.10176.
5. Zimmer L, Luxen A. PET radiotracers for molecular imaging in the brain: past, present and future. Neuroimage 2012;61:363-70, doi:10.1016/j.neuroimage.2011.12.037.
6. Henson JW, Gonzalez RG. Neuroimaging in glioma therapy. Expert Rev Neurother 2004;4:665-71, doi:10.1586/14737175.4.4.665.
7. Langen KJ, Ziemons K, Kiwit JCW, et al. 3-[I-123]Iodo-alphamethyltyrosine and [methyl-C-11]-L-methionine uptake in cerebral gliomas: A comparative study using SPECT and PET. J Nucl Med 1997;38:517-22.
8. Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: A comparison between [F-18]fluorodopa and [C-11] methionine. Eur J Nucl Med Mol Imaging 2003;30:1561-7, doi:10.1007/s00259-003-1259-1.
9. Fueger BJ, Czernin J, Cloughesy T, et al. Correlation of 6-F-18- fluoro-L-Dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010;51: 1532-8, doi:10.2967/jnumed.110.078592.
10. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7, doi:10.1038/256495a0.
11. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
12. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immun 2003;52:281-96.
13. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50:248-64.
14. Salsano M, Treglia G. PET imaging using radiolabled antibodies: future direction in tumor diagnosis and correlate applications. Res Rep Nucl Med 2013;3:9-17.
15. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341:1192-8, doi:10.1126/science.1241145.
16. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10:165-80, doi:10.1038/nrc2806.
17. Hirai H, Maru Y, Hagiwara K, et al. A novel putative tyrosine kinase receptor encoded by the Eph gene. Science 1987;238: 1717-20, doi:10.1126/science.2825356.
18. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008;133:38-52, doi:10.1016/j.cell.2008.03.011.
19. Pasquale EB. EPH receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6:462-75, doi:10.1038/nrm1662.
20. Liu FH, Park PJ, Lai W, et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 2006;66: 10815-23, doi:10.1158/0008-5472.CAN-06-1408.
21. Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 2008;19: 151-6, doi:10.3892/or.19.1.151.
22. Zhuang GL, Brantley-Sieders DM, Vaught D, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010;70:299-308, doi:10.1158/0008-5472.CAN-09-1845.
23. Han LQ, Dong ZM, Qiao YH, et al. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 2005;99:278-86, doi:10.1016/j.ygyno.2005.06.036.
24. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005;9:1179-87, doi:10.1517/14728222.9.6.1179.
25. Margaryan NV, Strizzi L, Abbott DE, et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther 2009;8:275-84, doi:10.4161/cbt.8.3.7485.
26. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10:5145-50, doi:10.1158/1078-0432.CCR-03- 0589.
27. Lackmann M, Boyd AW. Eph, a protein family coming of age: more confusion, insight, or complexity?. Science Signaling 2008; 1:1-16, doi:10.1126/stke.115re2.
28. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a gliomaassociated antigen: A novel target for glioma vaccines. Neoplasia 2005;7:717-22, doi:10.1593/neo.05277.
29. Wen P, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep 2004;4:218-27, doi:10.1007/s11910-004-0042-4.
30. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005;3:541-51, doi:10.1158/1541-7786.MCR-05-0056.
31. Day B, Stringer B, Wilson J, et al. Glioma surgical aspirate: A viable source of tumor tissue for experimental research. Cancers 2013;5: 357-71, doi:10.3390/cancers5020357.
32. Xi HQ, Wu XS, Wei B, Chen L. Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med 2012;16:2894-909, doi:10.1111/j.1582-4934.2012.01612.x.
33. Wang S, Placzek WJ, Stebbins JL, et al. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem 2012;55:2427-36, doi:10.1021/jm201743s.
34. Jackson D, Gooya J, Mao SL, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 2008;68:9367-74, doi:10.1158/0008-5472.CAN-08- 1933.
35. Vearing C, Lee FT, Wimmer-Kleikamp S, et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumortargeting reagents. Cancer Res 2005;65:6745-54, doi:10.1158/0008-5472.CAN-05-0758.
36. Cai WB, Ebrahimnejad A, Chen K, et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 2007;34:2024-36, doi:10.1007/s00259-007-0503-5.
37. Xiong CY, Huang MA, Zhang R, et al. In vivo small-animal PET/CT of EphB4 receptors using Cu-64-labeled peptide. J Nucl Med 2011;52:241-8, doi:10.2967/jnumed.110.081943.
38. Zhang R, Xiong CY, Huang M, et al. Peptide-conjugated polymeric micellar nanoparticles for dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 2011; 32:5872-9, doi:10.1016/j.biomaterials.2011.04.070.
39. Mamat C, Mosch B, Neuber C, et al. Fluorine-18 radiolabeling and radiopharmacological characterization of abenzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4. Chemmedchem 2012;7:1991-2003, doi:10.1002/cmdc.201200264.
40. Clark MJ, Homer N, O'Connor BD, et al. U87MG decoded: The genomic sequence of a cytogenetically aberrant human cancer cell line. Plos Genet 2010;6:1-16, doi:10.1371/journal.pgen. 1000832.
41. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110, doi:10.1016/j.ccr.2009.12.020.
42. Pollard SM, Yoshikawa K, Clarke ID, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4:568-80, doi:10.1016/j.stem.2009.03.014.
43. Meares CF, McCall MJ, Reardan DT, et al. Conjugation of antibodies with bifunctional chelating-agents - isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal-ions. Anal Biochem 1984;142: 68-78, doi:10.1016/0003-2697(84)90517-7.
44. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PETMRI: A new approach for functional and morphological imaging. Nat Med 2008;14:459-65, doi:10.1038/nm1700.
45. Ait-Mohand S, Fournier P, Dumulon-Perreault VR, et al. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconj Chem 2011;22:1729-35, doi:10.1021/bc2002665.
46. Cooper MS, Ma MT, Sunassee K, et al. Comparison of Cu-64- complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability. Bioconj Chem 2012;23:1029-39, doi:10.1021/bc300037w.
47. Zhang Y, Hong H, Engle JW, et al. Positron emission tomography imaging of CD105 expression with a Cu-64-labeled monoclonal antibody: NOTA is superior to DOTA. Plos One 2011;6:1-7.
48. Boswell CA, Mundo EE, Zhang C, et al. Differential effects of predosing on tumor and tissue uptake of an In-111-labeled anti- TENB2 antibody-drug conjugate. J Nucl Med 2012;53:1454-61, doi:10.2967/jnumed.112.103168.
49. Bumbaca D, Xiang H, Boswell CA, et al. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol 2012;166:368-77, doi:10.1111/j.1476-5381.2011.01777.x.